Efficacy and safety of stereotactic radiotherapy in patients with HER2-positive breast cancer brain metastases following intracranial oligoprogression - Top-Institutions - MDSpire

Efficacy and safety of stereotactic radiotherapy in patients with HER2-positive breast cancer brain metastases following intracranial oligoprogression

  • By

  • Dongxing, Shen

  • Longyu, Zhu

  • Jun, Zhang

  • Deyou, Kong

  • Zhikun, Liu

  • May 31, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Mass General Brigham Cancer Institute
    Mass General Brigham Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology

  • #2

    Brigham and Women’s Hospital
    Brigham and Women’s Hospital

    Boston, MA

    Key Differentiators

    • Oncology

  • #3

    Fourth Hospital of Hebei Medical University
    Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei

    Key Differentiators

    • Oncology

  • #4

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Oncology

  • #5

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Oncology

Original Source(s)

Efficacy and safety of stereotactic radiotherapy in patients with HER2-positive breast cancer brain metastases following intracranial oligoprogression

  • by Dongxing, Shen , Longyu, Zhu , Jun, Zhang , Deyou, Kong , Zhikun, Liu

  • May 31, 2026

Related Content

The lactylation axis: bridging metabolic reprogramming and immunosuppression in the tumor microenvironment

A screening model for advanced colorectal neoplasia based on tumor markers and inflammatory indices: a retrospective study with an online risk calculator

Editorial: Harnessing machine learning for enhanced biomedical diagnosis and early disease detection: bridging data science and healthcare